Cocrystal Pharma Inc. (NASDAQ: COCP) has started dosing the first subjects in a Phase 1b clinical study evaluating CDI-988 for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE